Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Aug 22;11(8):e007613. doi: 10.1136/jitc-2023-007613

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Long-term follow-up reveals a subset of extraordinary responders after treatment with cisplatin-based chemotherapy and ipilimumab. (A) Kaplan-Meier survival curve with the four DDFTFS patients labeled (MG36, MG08, MG35, MG25). (B) Swimmer plot indicating the duration of treatment, clinical response, and time of progression, death/censor, or ongoing response, with DDFTFS patients bolded. CR, complete response; DDFTFS, durable disease-free treatment-free survival; PD, progressive disease; PR, partial response; SD, stable disease.